Lv1
40 积分 2024-07-16 加入
Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough
11天前
已完结
Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant
11天前
已完结
Treatment of chronic cough: P2X3 receptor antagonists and beyond
11天前
已完结
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
11天前
已完结
Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose–response meta-analysis of randomized controlled trials
11天前
已完结
Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study
14天前
已完结
Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study
15天前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
18天前
已完结
Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation
22天前
已完结
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
1个月前
已完结
皖公网安备34019202002308
